Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
about
Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsGoing viral: a review of replication-selective oncolytic adenovirusesAdenovirus vectors for gene therapy, vaccination and cancer gene therapyRNA interference and potential therapeutic applications of short interfering RNAsTumor-specific delivery of biologics by a novel T-cell line HOZOT.Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.Short interfering RNA (siRNA) as a novel therapeutic.Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Directed evolution generates a novel oncolytic virus for the treatment of colon cancerInduction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factorExpanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusEvaluation of adenovirus capsid labeling versus transgene expressionChemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusCancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactionsBio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.Viral and nonviral delivery systems for gene deliverySelective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.Gene therapy for cancer treatment: past, present and futureMethods for screening tumors for p53 status and therapeutic exploitation.Progress and perspectives in chemoprevention of head and neck cancer.Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.Gene Therapies for Cancer: Strategies, Challenges and Successes.Increasing the efficacy of oncolytic adenovirus vectorsParvovirus vectors for cancer gene therapy.Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Gene therapy in orthopaedic surgery: the current status.Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerTherapeutic efficacy of paclitaxel and carboplatin via arterial or venous perfusion in rabbits with VX-2 tongue cancer.Endostatin gene therapy for liver cancer by a recombinant adenovirus deliveryIntravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Adenovirus as vehicle for anticancer genetic immunotherapy.
P2860
Q25257260-60A46DA6-E7FD-431E-A2A1-CA3F92CFE848Q26776553-C22CCE75-1209-4973-81AA-CC64E5D52050Q26797520-D6C6045F-A60C-4477-8AB1-30D14E5900B0Q27001601-0DE2D3FB-7918-40A5-B758-5C796BCEE58CQ28250480-EFDE7035-F052-417E-AC4A-C9E5BA9FB015Q30830225-247D1C41-3749-413C-9BF3-09C9E2283E64Q33221159-B1BDBEAA-9DB9-44FE-A79C-04A8557317E9Q33243420-ABDAC96A-29FC-4D01-B729-AE0634E9B9C9Q33259239-FF31AB03-8633-42BB-A10C-E325DDADA43AQ33344440-1C74FEB8-034D-4EA6-A1D7-583EC242D9A7Q33387265-77666EFA-E453-403E-A5FB-1107E0CB333FQ33622711-83BC41BC-DFFD-4A0D-8596-3DE2EE63FFCDQ33633287-1124FD46-9AEB-46BE-9F33-4F2C07BC73B2Q33669272-D2CFA274-5E0B-4339-82B0-D7A050AF8F4AQ33690982-9D4BC076-F702-4FC3-91A2-6961A7505C15Q33713324-F781A27C-BC96-402B-A652-C068930B7F3DQ33771285-7E7C049F-D55C-45CD-A483-9902D5BB4859Q33803963-0F6C6CDE-CBC3-4ED0-8265-A62BE256C187Q34025129-39E3C837-D262-4D10-9287-17DE8F48F935Q34091152-F03B75FB-F632-46B0-A7E9-E20D52E03725Q34315475-4B26ACA7-D7F6-40E7-9B5B-8C1F1F188AC9Q34659341-3A2905E2-AE64-44B3-9D18-441876539042Q34667746-9CD3CE97-BD88-4708-9781-648A5DB26664Q35040146-DCA5094A-9FA1-4D38-808E-D4ECD8BE4040Q35142162-5913288D-02AF-461A-9F38-70AD4849ABABQ35160205-CA951B0C-E51C-45B1-8780-C605463572CDQ35174932-0BA7BE9A-1868-4242-AC29-810F9E630B2AQ35186312-BC37A39B-57AB-4999-AD35-60D9693756C6Q35261325-1DFC4A98-57AD-4AF5-B922-59820B854562Q35609780-3C656733-288C-4B24-8BEA-B2B7D0074AD1Q35618835-FC006860-2E00-4EC1-989D-109282997B45Q35630146-3187BAC7-5512-4ABC-8431-F643B12466F1Q35665175-B7CC5045-1974-48A1-8452-8B79DBD2AF28Q35791394-20640F39-C2DF-434B-B615-C0D2C0FFE78FQ36065853-92B2FD5A-4526-4DC6-A445-FD20BA3E6ECBQ36179390-A6A49EB4-25A2-4782-9408-97FAE4B26855Q36209165-EB45ACC2-5174-4D72-90EE-FAD4A50E3B60Q36209172-C46C4C47-5E12-4749-9F54-F54552C7EA86Q36258513-77DD42C0-3879-4F5C-847E-51631AF378D7Q36288930-F8CE5761-3342-4929-81A9-7CB0363F53B3
P2860
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
@en
type
label
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
@en
prefLabel
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
@en
P2093
P2860
P356
P1433
P1476
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
@en
P2093
David Kirn
Robert Warren
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700539
P577
2002-12-01T00:00:00Z